February 22, 2018 / 12:21 PM / 6 months ago

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Feb 22 (Reuters) - Gilead Sciences Inc will use Sangamo Therapeutics Inc’s gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, the companies said in a joint statement. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D’Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below